Onyx Pharmaceuticals' shares rose as much as 13 percent Tuesday after the company said data showed that its experimental drug carfilzomib shrank tumours in a third of patients with multiple myeloma in a mid-stage trial. Results of the study, which were presented at the ASH meeting, demonstrated that among 257 patients who had failed to improve on previous treatments, 24 percent had their cancer reduced by half, while 10 percent had malignancy reduced by one-quarter. Onyx CMO Michael Kauffman said the company would use the results to seek accelerated approval from US regulators by the middle of next year.
Reference Articles
Onyx drug reduced cancer in patients with myeloma - (Bloomberg)
Onyx: myeloma trial, side effects look favorable - (Fidelity)
Onyx Pharmaceuticals announces positive complete results from carfilzomib Phase 2b study - (Onyx Pharmaceuticals)
Onyx Pharma reports positive complete results from carfilzomib Phase 2b study - (Stock Markets Review)
**Published in "First Word"
No comments:
Post a Comment